Informacje
Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education of the Republic of Poland (2010-2012). He was a President of Polish Mother's Memorial Hospital - Research Institute (PMMHRI) (February 2014-March 2021), He is Head of Cardiovascular Research Centre at University of Zielona Gora, full Professor of Cardiology at the Medical University of Lodz (MUL) and PMMHRI, Head of Foreign Affairs Office (2012-2014), Head of Department of Hypertension (2008-) at the Medical University of Lodz and Professor in the Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, at the WAM University Hospital in Lodz, Poland (2009-).
He is a Secretary of the European Atherosclerosis Society (EAS) (2021-2024) and member of the Scientific and Health Policy Advisory Group of the FH Europe. He is a Founder and Head of the Polish Lipid Association (PoLA) (2011-) and Lodz Chapter of Polish Society of Hypertension (2009-). He is the founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC; lbpmcgroup.umed.pl) Group (2012-) – a group of over 150 worldwide experts aimed to investigate the most important issues in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the International Lipid Expert Panel (ILEP; ilep.eu) (2015-), currently with >50 national society members, which has been founded to prepare recommendations in the area of preventive cardiology in the most debatable issues that have not been covered in the existing guidelines. He is also a member of the REPROGRAM Consortium – a group of experts challenging with Covid-19 pandemic, member of 2 largest worldwide databases – the Global Burden of Disease (GDB) (University of Washington, Seattle, US) and Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health research institutes and over 40 medical business representatives in Poland with main aim to make innovations in the medical area in Poland.
Prof. Banach has published >1000 papers with combined IF >10,000 pts, number of citations: 26865 (acc. WoS-CC), 27,832 (SCOPUS), 32,121 (ResearchGate), and 41,563 (Google Scholar), Hirsch’s Index = 65 (WoS/Publons), 68 (SCOPUS), 75 (ResearchGate) and 83 (i10-index: 514) (Google Scholar) – being within 1% the highest cited scientists in the world according to ESI by Clarivate (with 40 TOP Papers).
Autor artykułów: Maciej Banach
-
Szczepionka anty-PCSK9 skuteczna w prewencji hipercholesterolemii i zapobiega miażdżycy!
Szczepionka anty-PCSK9 skuteczna w prewencji hipercholesterolemii i zapobiega miażdżycy!
Autor: Maciej Banach
-
Dlaczego całkowita izolacja ma sens? Dlaczego tak ważne jest właściwe zabezpieczenie personalu medycznego i schorowanych osób starszych?
Dlaczego całkowita izolacja ma sens? Dlaczego tak ważne jest właściwe zabezpieczenie personalu medycznego i schorowanych osób starszych?
Autor: Maciej Banach
-
Bal Charytatywny & Zbiórka na Stypendia na Realizację Marzeń dla Naszych Najzdolniejszych pacjentów!
Bal Charytatywny & Zbiórka na Stypendia na Realizację Marzeń dla Naszych Najzdolniejszych pacjentów!
Autor: Maciej Banach
Doświadczenie
-
the Liverpool Centre for Cardiovascular Science (LCCS)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Wykształcenie
Licencje i certyfikaty
Publikacje
-
Effects of Coenzyme Q10 on Statin-Induced Myopathy - A Meta-analysis of Randomized Controlled Trials.
Mayo Clin Proc. January 2015 Volume 90, Issue 1, Pages 24–34
OBJECTIVE:
To evaluate the efficacy of coenzyme Q10 (CoQ10) supplementation on statin-induced myopathy.
PARTICIPANTS AND METHODS:
We searched the MEDLINE, Cochrane Library, Scopus, and EMBASE databases (November 1, 1987, to May 1, 2014) to identify randomized controlled trials investigating the impact of CoQ10 on muscle pain and plasma creatine kinase (CK) activity as 2 measures of statin-induced myalgia. Two independent reviewers extracted data on study characteristics, methods, and…OBJECTIVE:
To evaluate the efficacy of coenzyme Q10 (CoQ10) supplementation on statin-induced myopathy.
PARTICIPANTS AND METHODS:
We searched the MEDLINE, Cochrane Library, Scopus, and EMBASE databases (November 1, 1987, to May 1, 2014) to identify randomized controlled trials investigating the impact of CoQ10 on muscle pain and plasma creatine kinase (CK) activity as 2 measures of statin-induced myalgia. Two independent reviewers extracted data on study characteristics, methods, and outcomes.
RESULTS:
We included 6 studies with 302 patients receiving statin therapy: 5 studies with 226 participants evaluated the effect of CoQ10 supplementation on plasma CK activity, and 5 studies (4 used in the CK analysis and 1 other study) with 253 participants were included to assess the effect of CoQ10 supplementation on muscle pain. Compared with the control group, plasma CK activity was increased after CoQ10 supplementation, but this change was not significant (mean difference, 11.69 U/L [to convert to μkat/L, multiply by 0.0167]; 95% CI, -14.25 to 37.63 U/L; P=.38). Likewise, CoQ10 supplementation had no significant effect on muscle pain despite a trend toward a decrease (standardized mean difference, -0.53; 95% CI, -1.33 to 0.28; P=.20). No dose-effect association between changes in plasma CK activity (slope, -0.001; 95% CI, -0.004 to 0.001; P=.33) or in the indices of muscle pain (slope, 0.002; 95% CI, -0.005 to 0.010; P=.67) and administered doses of CoQ10 were observed.
CONCLUSION:
The results of this meta-analysis of available randomized controlled trials do not suggest any significant benefit of CoQ10 supplementation in improving statin-induced myopathy. Larger, well-designed trials are necessary to confirm the findings from this meta-analysis.Other authorsSee publication -
Analysis of vitamin D levels in patients with and without statin-associated myalgia - A systematic review and meta-analysis of 7 studies with 2420 patients.
Int J Cardiol. 2015 Jan 15;178:111-116.
INTRODUCTION:
Vitamin D (vit D) deficiency may be associated with an increased risk of statin-related symptomatic myalgia in statin-treated patients. The aim of this meta-analysis was to substantiate the role of serum vitamin D levels in statin-associated myalgia.
METHODS:
The search included PUBMED, Cochrane Library, Scopus, and EMBASE from January 1, 1987 to April 1, 2014 to identify studies that investigated the impact of vit D levels in statin-treated subjects with and without…INTRODUCTION:
Vitamin D (vit D) deficiency may be associated with an increased risk of statin-related symptomatic myalgia in statin-treated patients. The aim of this meta-analysis was to substantiate the role of serum vitamin D levels in statin-associated myalgia.
METHODS:
The search included PUBMED, Cochrane Library, Scopus, and EMBASE from January 1, 1987 to April 1, 2014 to identify studies that investigated the impact of vit D levels in statin-treated subjects with and without myalgia. Two independent reviewers extracted data on study characteristics, methods and outcomes. Quantitative data synthesis was performed using a fixed-effect model.
RESULTS:
The electronic search yielded 437 articles; of those 20 were scrutinized as full texts and 13 studies were considered unsuitable. The final analysis included 7 studies with 2420 statin-treated patients divided into subgroups of patients with (n=666 [27.5%]) or without (n=1754) myalgia. Plasma vit D concentrations in the symptomatic and asymptomatic subgroups were 28.4±13.80ng/mL and 34.86±11.63ng/mL, respectively. The combination of data from individual observational studies showed that vit D plasma concentrations were significantly lower in patients with statin-associated myalgia compared with patients not manifesting this side effect (weighted mean difference -9.41ng/mL; 95% confidence interval: -10.17 to -8.64; p<0.00001).
CONCLUSIONS:
This meta-analysis provides evidence that low vit D levels are associated with myalgia in patients on statin therapy. Randomized controlled trials are necessary to establish whether vitamin D supplementation reduces the risk for statin-associated myalgia.Other authorsSee publication -
Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication
International Journal of Cardiology
Our analysis of REGARDS data on the optimal BP levels in eldery has been finally published! It is very important study which confirms that there are still significant benefits to reduce BP to levels below 140 for older adults with HTN, what is also not associated with the increased number of falls. Nice Reading!
Other authorsSee publication -
Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials
Current medical research and opinion
-
The effects of statins on blood pressure in normotensive or hypertensive subjects - A meta-analysis of randomized controlled trials
International Journal of Cardiology
OBJECTIVE:
The aim of this meta-analysis was to investigate whether statin therapy is associated with blood pressure (BP)-lowering in patients with or without hypertension.
BACKGROUND:
The beneficial effects of statins on the cardiovascular system may in part be related to effects beyond lipid-lowering. It has been suggested that statins may reduce BP; however the available data are still ambiguous and often conflicting.
METHODS:
Data from Scopus, PubMed…OBJECTIVE:
The aim of this meta-analysis was to investigate whether statin therapy is associated with blood pressure (BP)-lowering in patients with or without hypertension.
BACKGROUND:
The beneficial effects of statins on the cardiovascular system may in part be related to effects beyond lipid-lowering. It has been suggested that statins may reduce BP; however the available data are still ambiguous and often conflicting.
METHODS:
Data from Scopus, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials for the years 1966-January 2012 were searched for studies that investigated the effect of statins on BP in normotensive or in hypertensive subjects. We included all randomized controlled clinical trials that investigated this effect. Changes in systolic and diastolic BP were the key outcomes of interest.
RESULTS:
The final analysis included 18 trials and 5628 subjects (4692 normotensive and 936 hypertensive patients) randomized to receive either statins or placebo. The weighted mean difference of systolic (∆SBP) and diastolic blood pressure (∆DBP) in normotensive patients for the 11 statin trials included were 0.03 (95% CI: -0.95-1.02; p=0.95) and -0.28 (95% CI: -0.80-0.24; p=0.29), respectively. For hypertensive patients treated with statins (8 trials) the weighted mean difference of ∆SBP and ∆DBP were 1.45 (95% CI: -0.49-3.39; p=0.14) and -1.32 (95% CI: -3.93-1.28; p=0.32) respectively.
CONCLUSIONS:
Despite previous suggestions statin therapy in normotensive or hypertensive patients does not lead to significant reductions in systolic or diastolic BP.
See: http://www.ncbi.nlm.nih.gov/pubmed/23602289Other authorsSee publication
Wyróżnienia i nagrody
-
“Gold Scalpel” Distinction in 2019 for the Innovation (Smart Hospital)
"Puls Medycyny" Journal
-
Doctor Honoris Causa
Carol Davila University of Medicine and Pharmacy in Bucharest, Romania
-
Honorary Member of the Romanian Society o Cardiology
Romanian Society o Cardiology
-
Doctor Honoris Causa
National Scientific Center MD Strazhesko Institute of Cardiology
-
Gold Honorary Medal for the Scientific Achievements
Medical Faculty of Medical University in Kosice, Slovak Republic
-
The Manager of the Year 2016 – Public Entities
Termedia Publishing House
-
Doctor Honoris Causa
University of Medicine and Pharmacy Victor Babes in Timisoara, Romania
-
Innovator of the Year – Science Category
Wprost Journal
-
Gold Scalpel” Distinction in 2016 for the Innovation (Modernization of the Polish Healthcare System)
Puls Medycyny Journal
-
The Personality of the Year 2013 in Poland for the Development of Science in the Field of Healthcare
Heath Manager journal (Termedia Publishing House)
-
Super-Talent in Medicine 2012 Award
Puls Medycyny Journal
The winner of the competition for young scientists in medicine in Poland (up to 40).
Języki
-
angielski
-
Organizacje
-
Lipids and Blood Pressure Meta-analysis Collaboration Group (LBP-MAC Group)
Founder / Member
– obecnie -
Alliance for Biomedical Research
Member of the Working Core
– obecnieThe Alliance for Biomedical Research (http://www.biomedeurope.org/) in Europe (BioMed Alliance) was founded by four major European academic medical societies namely the European Cancer Association (ECCO), the European Respiratory Society (ERS), the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Since December 2010 the BioMed Alliance is officially established as a non-profit association and registered in Belgium. There were several reasons…
The Alliance for Biomedical Research (http://www.biomedeurope.org/) in Europe (BioMed Alliance) was founded by four major European academic medical societies namely the European Cancer Association (ECCO), the European Respiratory Society (ERS), the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Since December 2010 the BioMed Alliance is officially established as a non-profit association and registered in Belgium. There were several reasons for founding the BioMed Alliance including the growing concerns by European scientists that we are losing our international competitiveness due to insufficient funding, the complicated and excessive administrative burdens on scientists applying and/or receiving EU support, promote the influence of active scientists on European research plans and their implementations as well as concerns over the fragmented European science funding in the health area. The Alliance for Biomedical Research in Europe (BioMed Alliance) is a unique initiative representing 21 leading research-oriented medical societies that include more than 250.000 researchers across Europe. The BioMed Alliance is committed through its actions to promote excellence in European biomedical research and innovation with the goal of improving the health and well-being of all European citizens.
-
European Innovation Partnership on Active and Healthy Ageing
Member of the Steerring Committee
–With the Innovation Union strategy the European Commission aims to enhance European competitiveness and tackle societal challenges through research and innovation. One way in which this is to be achieved is with Innovation Partnerships. Their unique strength is that they will address weaknesses in the European research and innovation system (notably, under-investment, conditions which are not sufficiently innovation-friendly, and fragmentation and duplication), which considerably complicate…
With the Innovation Union strategy the European Commission aims to enhance European competitiveness and tackle societal challenges through research and innovation. One way in which this is to be achieved is with Innovation Partnerships. Their unique strength is that they will address weaknesses in the European research and innovation system (notably, under-investment, conditions which are not sufficiently innovation-friendly, and fragmentation and duplication), which considerably complicate the discovery or exploitation of knowledge and, in many cases, ultimately prevent the entry of innovations into the market place. The European Commission has identified active and healthy ageing as a major societal challenge common to all European countries, and an area which presents considerable potential for Europe to lead the world in providing innovative responses to this challenge. The pilot European Innovation Partnership on Active and Healthy Ageing will pursue a triple win for Europe: 1.enabling EU citizens to lead healthy, active and independent lives while ageing; 2.improving the sustainability and efficiency of social and health care systems; 3.boosting and improving the competitiveness of the markets for innovative products and services, responding to the ageing challenge at both EU and global level, thus creating new opportunities for businesses. This will be realised in the three areas of prevention and health promotion, care and cure, and active and independent living of elderly people. The overarching target of this pilot partnership will be to increase the average healthy lifespan by two years by 2020. The pilot Partnership will aim to achieve this by bringing together key stakeholders (end users, public authorities, industry); all actors in the innovation cycle, from research to adoption (adaptation), along with those engaged in standardisation and regulation.
Inne podobne profile
Inne osoby o nazwisku Maciej Banach w kraju Polska
18 innych osób o nazwisku Maciej Banach z kraju Polska jest na LinkedIn
Zobacz innych o nazwisku Maciej Banach